Summary & Overview
HCPCS J7677: Revefenacin Inhalation Solution via DME, 1 mcg
HCPCS Level II code J7677 identifies revefenacin inhalation solution, an FDA-approved, non-compounded respiratory medication supplied for administration through durable medical equipment at a dose of 1 microgram. This code matters nationally as inhaled bronchodilators and nebulized solutions billed through DME channels are integral to outpatient and home-based care for chronic respiratory conditions. Proper coding supports accurate coverage determination, claims processing, and program integrity across payer types.
Key payers discussed include Aetna, Blue Cross Blue Shield, Cigna Health, UnitedHealthcare, and Medicare. Readers will find a concise orientation to the clinical and administrative context of J7677, including typical service settings and how the product is described for billing purposes. The publication covers benchmarks and coverage considerations relevant to national payers, highlights common billing modifiers used with DME-delivered drugs, and summarizes policy and reimbursement implications for outpatient and home infusion/respiratory therapy programs.
This executive summary prepares clinicians, billers, and policy analysts to understand where J7677 fits in respiratory drug billing, what payers commonly encounter it, and which operational areas—claims coding, DME coordination, and payer policy—are most affected. Data not available in the input is noted where applicable.
Billing Code Overview
HCPCS Level II code J7677 represents revefenacin inhalation solution, FDA-approved final product, non-compounded, supplied for administration through durable medical equipment. The product strength is specified as 1 microgram per the billing description.
Service Type: Respiratory drug administration via DME
Typical Site of Service: Home or outpatient setting using durable medical equipment (DME)
Data not available in the input.
Clinical & Coding Specifications
Clinical Context
A 68-year-old patient with a history of chronic obstructive pulmonary disease (COPD) with persistent symptoms despite maintenance inhaled bronchodilator therapy presents for medication administration and monitoring. The patient is prescribed inhaled revefenacin, an FDA-approved nebulized long-acting muscarinic antagonist supplied as a final, non-compounded solution. The medication is dispensed through durable medical equipment (DME) and administered via a home or clinic-based nebulizer system.
The clinical workflow includes: initial prescription by a pulmonary specialist or primary care provider; DME supplier shipment of the FDA-approved J7677 product in the unit dose specified; verification of patient identity, indication, and insurance coverage by the DME provider; instruction and demonstration of nebulizer setup and administration either in clinic or via a home visit or telehealth training; documentation of dosing (microgram amount per vial), date of service, and any adverse reactions; and periodic follow-up visits with spirometry or symptom assessment to evaluate therapeutic response and need for continued therapy.
Coding Specifications
| Modifier | Description | When to Use |
|---|---|---|
JW | Drug discarded/partial dose | Use when a portion of the single-use J7677 vial is discarded and must be reported per payer policy. |